Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
Authors
Discussion
Loading...
Member takes
Implication
A nested case-control study finds no association between baseline plasma PCSK9 levels and incident cardiovascular events in healthy women, indicating limited value as a prognostic biomarker.
Key Points
- To evaluate whether baseline plasma concentrations of proprotein convertase subtilisin/kexin type 9 (PCSK9) predict incident cardiovascular events in initially healthy women.
- Nested case-control study within a prospective cohort of >28 000 initially healthy American women followed for 17 years.
- Measured baseline plasma PCSK9 concentrations in 358 participants who developed major cardiovascular events and 358 control participants matched by age, smoking status, and hormone replacement therapy.
- Baseline PCSK9 levels were positively associated with apolipoprotein B-100 (r = 0.20, P < 0.001) and triglycerides (r = 0.13, P = 0.004), but not with smoking, hypertension, obesity, HDL cholesterol, lipoprotein(a), or hs-CRP.
- Baseline PCSK9 levels did not predict first cardiovascular events across ascending quartiles (ORs: 1.0 [referent], 0.94, 0.98, and 1.15; P-trend = 0.53).
- In contrast, baseline apolipoprotein B levels strongly predicted cardiovascular events across quartiles (ORs: 1.0 [referent], 1.14, 1.34, and 1.94; P-trend = 0.002).
Cite This Study
Ridker et al. (2015) studied this question.